Progress and challenges for malaria vaccines

Nature

Volumn 415, Issue 6872, 2002, Pages 694-701

  Richie, Thomas L ^a   Saul, Allan ^a  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; MEDICAL PROBLEMS; VACCINES;

CLINICAL TRIALS;

MALARIA CONTROL;

ANTIGEN; ANTIGEN AMA1; ANTIGEN CSP; ANTIGEN EXP1; ANTIGEN GLURP; ANTIGEN LSA1; ANTIGEN LSA3; ANTIGEN MSP1; ANTIGEN MSP2; ANTIGEN MSP3; ANTIGEN MSP4; ANTIGEN PF155; ANTIGEN PF332; ANTIGEN PFEMP1; ANTIGEN PFS230; ANTIGEN PFS25; ANTIGEN PFS28; ANTIGEN PFS48; ANTIGEN PIEBA175; ANTIGEN PVDABP; ANTIGEN RAP1; ANTIGEN RAP2; ANTIGEN RESA; ANTIGEN SALSA; ANTIGEN SERA; ANTIGEN SSP2; ANTIGEN STARP; ANTIGEN TRAP; MALARIA VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DISEASE CONTROL; MALARIA; RESEARCH AND DEVELOPMENT; VACCINATION;

CLINICAL TRIAL; DEVELOPING COUNTRY; DRUG DESIGN; DRUG RESEARCH; HUMAN; MALARIA; MALARIA CONTROL; PRIORITY JOURNAL; REVIEW; TROPICS; VACCINATION;

ANIMALS; CHRONIC DISEASE; CLINICAL TRIALS; DRUG DESIGN; HUMANS; MALARIA; MALARIA VACCINES;

PROTOZOA;

EID: 0037033980     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/415694a     Document Type: Review

References (88)

1. Epidemiological significance of repeated infections with homologous and heterologous strains and species of Plasmodium
2. Immunity to falciparum and vivax malaria induced by irradiated sporozoites: A review of the University of Maryland studies, 1971-75
3. Malaria transmission and morbidity
4. Plasma antibodies from malaria-exposed pregnant women recognize variant surface antigens on Plasmodium falciparum-infected erythrocytes in a parity-dependent manner and block parasite adhesion to chondroitin sulfate A
5. Malaria transmission-blocking vaccines - How can their development be supported?
6. The role of variant surface antigens on malaria-infected red blood cells
7. Evolution of the human genome under selective pressure from malaria: Applications for control
8. Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium berghei
9. Immunization of monkeys against Plasmodium cynomolgi by X-irradiated sporozoites
10. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites
11. Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria
12. Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes
13. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium sp. sporozoites
14. Host age as a determinant of naturally acquired immunity to Plasmodium falciparum
15. Naturally acquired antibodies to sporozoites do not prevent malaria: Vaccine development implications
16. Gamma globulin and acquired immunity to human malaria
17. Adult and cord-blood gamma globulin and immunity to malaria in Nigerians
18. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria
19. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria
20. Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial
21. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes
22. The surface variant antigens of Plasmodium falciparum contain cross-reactive epitopes
23. Measurement of Plasmodium falciparum growth rate in vivo: A test of malaria vaccines
24. Antigenic diversity of Plasmodium falciparum and antibody-mediated parasite neutralization
25. The complexity of protective immunity against liver-stage malaria
26. Transmission blocking malaria vaccines
27. Human malaria in immunocompromised mice: An in vivo model to study defense mechanisms against Plasmodium falciparum
28. Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal
29. Malaria vaccine development: Current status
30. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant
31. Construction and immunogenicity in mice of attenuated Salmonella typhi expressing Plasmodium falciparum merozoite surface protein 1 (MSP-1) fused to tetanus toxin fragment C
32. Vaccines for preventing malaria
33. A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types
34. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodiom falciparum malaria
35. Efficacy of RTS, S/ASO2 malaria vaccine against P. falciparum infection in semi-immune adult men in The Gambia: A randomised trial
36. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a Phase I/IIb trial in Papua New Guinea
37. DNA vaccination as an approach to malaria control: Current status and strategies
38. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein
39. Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8′ cell-, interferon γ-, and nitric oxide-dependent immunity
40. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
41. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers
42. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine
43. + type 1 responses in humans by a malaria DNA vaccine
44. Multi-stage multi-antigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques
45. Induction of protective immune responses in rhesus monkey by immunization with recombinant plasmids of polyvalent epitopes of Plasmodlum falciparum using cholera toxin B as adjuvant
46. First DNA malaria vaccine on trial in Africa
47. Malaria DNA vaccines in Aotus monkeys
48. Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine
49. Enhancement of the immune response in rabbits to a malaria DNA vaccine by immunization with a needle-free jet device
50. A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees
51. Codon optimization of gene fragments encoding Plasmodium falciparum merozoite proteins enhances DNA vaccine protein expression and immunogenicity in mice
52. Targeting dendritic cells to enhance DNA vaccine potency
53. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines
54. + T cell immunoganicity and protective efficacy in the influenza and malaria models
55. DNA immunization with Plasmodium falciparum serine repeat antigen: Regulation of humoral immune response by coinoculation of cytokine expression plasmid
56. A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine
57. Improving protective immunity induced by DNA-based immunization: Priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus
58. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys
59. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
60. + T cells using heterologous prime-boost immunisation strategies
61. Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen
62. Assessment of a vaccinia virus vectored multi-epitope live vaccine candidate for Plasmodium falciparum
63. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a poxvectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria
64. + T cell-mediated protective anti-malaria immunity elicited by recombinant adenovirus
65. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles
66. Are trials in new world monkeys on the critical path for blood-stage malaria-vaccine development?
67. New world monkey efficacy trials for malaria vaccine development: Critical path or detour?
68. The epidemiology of malaria in the Wosera area, East Sepik Province, Papua New Guinea, in preparation for vaccine trials. II. Mortality and morbidity
69. Child mortality and malaria transmission intensity in Africa
70. Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge
71. European malaria vaccine initiative
72. The global alliance for vaccines and immunization - A millennial challenge
73. Immunogenicity of four Plasmodium falciparum pre-erythrocytic antigens in Aotus lemurimus monkeys
74. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3
75. Merozoite surface protein-3: A malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes
76. Naturally acquired antibody responses to Plasmodium falciparum merozoite surface protein 4 in a population living in an area of endemicity in Vietnam
77. Biochemical, biophysical and functional characterization of bacterially expressed and refolded binding domain of Plasmodium vivax Duffy binding protein
78. Specificity of the protective antibody response to apical membrane antigen 1
79. Plasmodium falciparum: An epitope within a highly conserved region of the 47-kDa amino-terminal domain of the serine repeat antigen is a target of parasite-inhibitory antibodies
80. Efficacy of vaccines containing rhoptry-associated proteins RAP1 and RAP2 of Plasmodium falciparum in Saimiri boliviensis monkeys
81. Specificities of antibodies that inhibit merozoite dispersal from malaria-infected erythrocytes
82. A Robust neutralization test for Plasmodium falciparum malaria
83. 19 are a major component of the invasion-inhibitory response in individuals immune to malaria
84. Molecular mechanisms of Plasmodium falciparum placental adhesion
85. Neutralizing monoclonal antibodies to glycosylphosphatidylinositol, the dominant TNF-alpha-inducing toxin of Plasmodium falciparum: Prospects for the immunotherapy of severe malaria
86. DNA-based vaccines against malaria: Status and promise of the multistage malaria DNA vaccine operation
87. A multilateral effort to develop and test multi-stage, multi-gene DNA vaccines against Plasmodium falciparum malaria